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Background: The protease inhibitor (PI) darunavir (DRV) has proven to be highly effective
and well tolerated for HIV treatment. The DAD (Data collection on Adverse Effects of Anti-
HIV Drugs) cohort showed an increased 5-year cumulative cardiovascular (CV) risk in
patients given various PIs, including DRV, whereas two other recent studies found no
association between DRV and CV diseases.
Methods: We performed a post-hoc analysis of CV adverse events (CVAEs) in an Italian
cohort, the TMC114-HIV4042 observational study, where 875 patients treated with ritonavir-
boosted DRV-based regimens were followed for a total of 1,566 patient-years.
Results: We observed 23 CVAEs of any type, including 17 [12 (95%CI, 7–19) per 1,000
patient-years] primary; 14 [10 (95%CI, 5–17) per 1,000 patient-years] were primary
Framingham-type general CVAEs, close to what expected according to the Framingham
algorithm based on traditional risk factors. Age and systolic blood pressure (SBP) at the time
of study enrolment were the only relevant (p<0.01) independent predictors of CVAEs in all
models; patients with any CVAE were on average 10 years older and had an SBP 14 mmHg
higher than patients without CVAEs. When controlling for age and SBP, the association with
other traditional factors, including serum lipids, and with HIV-speciﬁc factors was not
statistically signiﬁcant (p>0.05). Models that also adjusted for previous ARV exposure
showed no statistically signiﬁcant association between any-type CVAEs and either DRV
doses, 1,200 or 800 mg/daily (as also suggested by propensity score stratiﬁcation), or
previous DRV exposure duration.
Conclusion: We found no evidence of a relationship between DRV use and increased
CV risk.
Keywords: HIV infection, darunavir, cardiovascular risk, observational study
Introduction
The prognosis of human immunodeﬁciency virus (HIV) infection had considerably
improved over the years since the introduction of highly active antiretroviral
therapy (HAART) two decades ago. With decreased mortality due to HIV-speciﬁc
causes, there has been an increasing prevalence in death due to non-infectious
causes, notably neoplastic and cardiovascular (CV) events.1 An analysis of the
DAD (Data collection on Adverse effects of anti-HIV Drugs) cohort showed an
increased 5-year cumulative risk of CV adverse events (CVAEs) in patients given
regimens based on protease inhibitors (PIs), including darunavir (DRV), compared
with the risk observed within populations unexposed to these drugs.2,3 On the other
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hand, a recent large analysis of data from pooled clinical
trials, pharmacovigilance reporting and US administrative
claims databases did not ﬁnd any signal for an association
between DRV and cardiovascular diseases (CVDs),4 and
a recent case-control study showed no evidence of an
increased risk of myocardial infarction (MI) following
exposure to DRV or atazanavir, another PI.5
TMC114-HIV4042 was a non-interventional study
aiming to collect data on the efﬁcacy and safety of anti-
retroviral (ARV) regimens based on darunavir/ritonavir
(DRV/r) in clinical practice; the main efﬁcacy and overall
safety results were previously published.6 The analysis
reported here aims to describe the CVAEs that occurred
during this observational study and to identify any predic-
tive factor that could be associated with CV risk.
Methods
Study design and execution
The TMC114-HIV4042 study was conducted as described
in Antinori et al.6 Both DRV-experienced and DRV-naïve
patients were enrolled. Some DRV-experienced patients,
referred to hereafter as ex-EAP, started DRV/r before
marketing authorization (July 2007), as part of the DRV/r
Early Access Program (EAP) (subjects included in the
EAP were heavily experienced, not achieving virological
suppression on their current regimen, were at risk of
clinical or immunological progression, and had limited or
no treatment options); the remaining DRV-experienced
patients, referred to hereafter as DRV-experienced not-
EAP, started DRV/r in routine clinical practice after mar-
keting authorization. The DRV-naïve group included both
ARV-experienced and ARV-naïve patients. Patients
received a DRV/r-based regimen in routine practice,
together with other active ARV drugs, and were observed
for 12–42 months up to the end 2012 or earlier disconti-
nuation. The study was approved by the ethical commit-
tees of the participating centers, as detailed in the
Supplementary materials. All patients provided written
informed consent for their data to be collected and used
in this study. The study was carried out following the
principles of the Declaration of Helsinki.
Deﬁnition of cardiovascular events and
cardiovascular risk factors
Hard CVAEs were deﬁned as cardiac death, MI and stroke,
according to the ACC/AHA atherosclerotic cardiovascular
disease (ASCVD) events deﬁnition,7 whereas the DAD
study deﬁnition also included invasive heart surgery.3
General CVAEs were deﬁned as the hard ACC/AHA
CVAEs plus congestive heart failure, coronary insufﬁ-
ciency, angina, transient ischaemic attack, and clinical
(ie, symptomatic) peripheral artery diseases, similarly to
the Framingham general CVD deﬁnition.8 The deﬁnition
of any CVAE included, in addition to the Framingham-
type general CVAEs, subclinical artery diseases such as
atherosclerosis and carotid artery occlusion or stenosis.
CVAEs were adjudicated after examination of the original
AE reports.
The baseline values for laboratory variables were
deﬁned as the value nearest to study entry from 90 days
before to 1 day after, included. The body mass index
(BMI) was computed as weight/height^2. The estimated
glomerular ﬁltration rate (eGFR) was obtained according
to the CKD-EPI equation.9 Serum low-density lipoprotein
(LDL) cholesterol levels were either directly measured
(14% of samples) or estimated from total and high-
density lipoprotein (HDL) cholesterol and triglyceride
levels using tables from the Very Large Database of
Lipids.10 Active diabetes at study entry was reviewed to
include antidiabetic drug use ongoing or started at baseline
or fasting serum glucose >125 mg/dL, as described in the
Framingham study.8
The Framingham general CVD 10-year risk was calcu-
lated as speciﬁed.8 The Framingham risk functions derive
from Cox models separate for males and females and
include age, systolic blood pressure (SBP), use of antihy-
pertensive medication (yes/no), serum total and HDL cho-
lesterol levels, current smoking status (yes/no) and
diabetes (yes/no). For the numerical values outside the
range for which the index was calculated (age 30–74 years,
SBP 90–200 mmHg, total cholesterol 100–405 mg/dL and
HDL cholesterol 10–100 mg/dL), the limit value exceeded
was used, as recommended in the spreadsheet calculator
implementing this instrument. A Framingham risk func-
tion using BMI instead of cholesterol levels and previously
shown to perform similarly8 was used in this study when
total or HDL cholesterol levels were missing. The hard
ACC/AHA CVD 10-year risk was calculated as a function
of age, gender, race, SBP, antihypertensive medication,
serum total and HDL cholesterol levels, smoking and
diabetes, as previously reported.7 The limit value exceeded
was used for the numerical values outside the validated
range (age 40–79 years, SBP 90–200 mmHg, total choles-
terol 130–320 mg/dL and HDL cholesterol
20–100 mg/dL).
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Statistical methods
The incidence rate (IR) of CVAEs was calculated as the
ratio between the number of events and the cumulative
follow-up duration; the exact 95% conﬁdence interval (CI)
of the Poisson distribution was estimated using the chi-
square method. Kaplan-Meier curves were obtained show-
ing CVAE incidence over time.
The expected number of Framingham-type CVAEs was
calculated as the sum of the individual probabilities with
methods similar to those described for the DAD
cohort.11,12 As the Framingham risk calculation is vali-
dated only for primary events, it was restricted to patients
without previous CVDs. Individual probabilities were
obtained from each patient’s Framingham general CVD
10-year risk8 and follow-up duration, assuming either the
Weibull accelerated failure time distribution as described
in former Framingham equations,13 or a constant rate. For
this calculation, the missing data required for the
Framingham score were imputed using surrogate informa-
tion, as detailed in the Supplementary materials. In
a sensitivity analysis, optimal values, ie, SBP
110 mmHg, total cholesterol 170 mg/dL, HDL cholesterol
50 mg/dL, no diabetes, no smoking and no antihyperten-
sive use, were imputed for missing data.
CVAE incidence by DRV dose was examined within
propensity score (PS) strata. The PS for DRV 600 mg bis
in die (b.i.d.), ie the probability of receiving that dose
rather than 800 mg quantum die (q.d.) given certain patient
characteristics, was obtained empirically by examining its
relationship, essentially nonlinear, with key features on
which DRV-dosage recommendations are based: previous
ARV therapy, HIV-RNA load or CD4+ counts.
The association between CVAEs and several possible
predictors was examined using Cox proportional-hazard
models. The predictors tested included the Framingham
10-year risk score, the variables used for its computation
(age, gender, smoking, SBP, antihypertensive medication,
diabetes, serum total and HDL cholesterol, and BMI),
other traditional factors (LDL cholesterol, triglycerides,
diastolic blood pressure, eGFR, statin medication, antic-
oagulant medication, and family history of CVD), and
HIV-speciﬁc variables (disease stage, HIV-RNA load,
CD4+ count, and history of intravenous drug use).
Models for Framingham-type CVAEs were studied in
patients without previous CVDs, as the Framingham
score was developed for primary events only. Models for
any-type CVAEs were analyzed in all patients, with or
without previous CVDs; CVD history was added to the
characteristics examined as potential prognostic factors.
Patients who were ARV-naïve at DRV start (who had no
CVAE during the study) were excluded from some ana-
lyses to reduce confounding by variables that represent
exposure to the disease and its therapy. The effect of
these exposure variables (duration of HIV infection, dura-
tion of ARV therapies, duration and dose of DRV therapy)
on any-type CVAEs was studied in models that included
both ARV-experienced and ARV-naïve patients; these ana-
lyses were adjusted for age and SBP at baseline, the most
relevant traditional factors. Subject exclusions from expo-
sure models were avoided by imputing, for missing data,
the most likely value based on surrogate information, as
detailed in the Supplementary materials. To avoid over-
parameterization, no more than two variables were
included in the same model of Framingham-type primary
CVAEs and up to four variables in models predicting any-
type CVAEs. Continuous variables were previously log-
transformed as indicated.7,8 Therefore, the hazard ratio
(HR) of each continuous variable was referred to
a relative increase of its value, by an amount (10%, 25%,
50% or 100%) chosen according to its range of variation.
The effects of the variables examined were assumed to be
proportional over time, as previously found.7,8 In our
sample, only statin use at baseline showed a signiﬁcant
interaction with time in models for any CVAE, however,
only large departures from proportionality might be
detected due to the small sample size.
Laboratory values at baseline and throughout the study
were summarised for patients with and without CVAEs;
Student’s two-sample t-tests were used for comparisons.
The statistical analyses were carried out using
SAS© 9.4.
Results
Patients and treatments
Eight hundred seventy-ﬁve patients were enrolled: 235
(DRV-experienced ex-EAP) were already receiving DRV/r
since July 2007 or earlier, 407 (DRV-experienced not EAP)
were already receiving DRV/r since August 2007 or later,
before the inclusion in this study, and 233 (DRV-naïve)
started DRV/r at entry in this study. Of the DRV-
experienced not EAP patients, 75 had received no ARV
therapy before DRV/r, like 117 patients enrolled in this
study as DRV-naïve; all other patients were ARV-
experienced at DRV initiation.
Dovepress Antinori et al
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The baseline characteristics are shown in Table 1. The
mean age was 46 years; 77.8% of the patients were men,
40.7% were in clinical stage C according to the Center for
Disease Control and Prevention (CDC) criteria, 49.1% were
active smokers, 15.7% were on antihypertensive therapy and
5.8% had diabetes; the mean serum total cholesterol was
189 mg/dL in the 748 patients with an available baseline
measure. Previous CVDs, either atherosclerotic in nature or
potentially related to atherosclerotic risk, were reported in
9.8% of the patients overall, including 25 (2.9%) withMI and
10 (1.1%) with stroke or cerebral haemorrhage, as detailed in
the Table S1.
ARV therapy before and during the study is reported in
Table 2, and a list of previously used ARV drugs is provided
in the Table S2. Most patients had a long history of treat-
ment with several ARV drugs, including 42% of ARV-
experienced patients which reported abacavir exposure.
The median overall exposure to previous ARV therapy
was 15 years in ex-EAP patients, 12 years in DRV-
experienced not EAP patients, and 10 years in the ARV-
experienced DRV-naïve cohort. The length of exposure to
each ARV drug was generally not available. The DRV dose
was mainly 600 mg b.i.d., in patients who had received
other ARV treatments before DRV start and mainly
800 mg q.d., in patients who were ARV-naïve at DRV
initiation. Tenofovir/emtricitabine was the background
therapy most used in this study; raltegravir was also fre-
quently used in ARV-experienced patients. The mean fol-
low-up duration during this study was about 21 months.
Incidence rates of cardiovascular events
A summary of the CVAEs reported in this study by pre-
vious CVD (yes or no), patient group and event type is
shown in Table 3. An individual description of all CVAEs
is provided in the Supplementary materials (Listing I). The
IR for general Framingham-type CVAEs in the whole
population was 12 per 1,000 patient-years overall (95%
CI, 7–19), 10 (5–17) as primary events and 32 (10–75) in
patients with previous CVDs. The IR for hard CVAEs in
the whole population was 8 per 1,000 patient-years overall
(95%CI, 4–14), 6 (3–12) and 26 (7–66) in patients without
and with previous CVDs, respectively. The hard DAD-
type events were the same as the hard ACC/AHA-type
CVAEs plus one (angioplasty with stent in a patient with
MI history). IRs were similar in the
ex-EAP, DRV-experienced not EAP, and ARV-
experienced DRV-naïve cohorts. No CVAEs were reported
in the 192 patients who were ARV-naive at the start of
DRV. The difference between the IRs observed in patients
with or without ARV therapies before DRV start was
statistically signiﬁcant (p=0.016, log-rank test).
The IRs remained relatively constant in all groups
throughout the study (Figure 1A and B).
Darunavir dose, background therapy and
cardiovascular events
The PS for DRV 600 mg b.i.d., ie, the probability of
receiving that dose rather than 800 mg q.d., is reported
in Table 4 as a function of previous ARV therapy, HIV-
RNA load or CD4+ counts. Almost all ex-EAP patients
were still receiving DRV 600 mg b.i.d at entry into this
study, as well as all non-EAP patients who were on DRV
for more than 3 years. Conversely, 89% of patients who
were ARV-naïve when DRV was started, received DRV
800 mg q.d. In the remaining DRV-experienced non-EAP
patient group, the PS for DRV 600 mg b.i.d. was increased
due to a longer history of ARV and DRV therapy, whereas
the preference for DRV 600 mg b.i.d in the DRV-naïve
ARV-experienced cohort was mainly determined by higher
HIV-RNA load and lower CD4+ counts at study entry. The
crude incidence of any CVAEs in the patient subsets with
different PS for DRV 600 mg b.i.d. is shown in Table 4.
Patients with no ARV therapy before DRV start, whose PS
for DRV 600 mg b.i.d. was <0.15, had no CVAEs; CVAEs
occurred only in patients with previous ARV therapy,
whose PS for DRV 600 mg b.i.d. ranged from 0.5 to 1.
Therefore, although the crude rate of CVAEs was greater
in patients receiving DRV 600 mg b.i.d., this was largely
due to a confounding by the previous ARV therapy, and it
was no longer observed when comparing IRs within dose
PS strata (Table 5). In the group having PS for 600 mg b.i.
d. of 0.50–0.65, where both DRV doses were similarly
represented, the IR for any CVAE was slightly higher
with 600 mg b.i.d., but this was not true for general and
hard CVAEs; the IRs in the other strata are hardly compar-
able due to the small number of patients given one of the
alternative doses (Table 5 and Supplementary materials,
Table S3).
For the patients who had CVAEs, exposure to the two
different doses of DRV and to background ARV drugs
before and during the study is listed in the
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Supplementary materials (Listing II). Of the 23 patients
with any CVAEs, 14 were exposed to abacavir (11 only
before study start, 2 also during the study and 1 from study
start), including 9 of 17 with primary events; most of these
patients were heavily exposed to other ARV therapies,
having a median ARV duration before study start of
748 weeks.
Cardiovascular risk scores and
cardiovascular events
The Framingham general CVD 10-year risk score at
study entry was calculated in 626 (79.3%) of all 789
patients without previous CVDs including 485/604
(80.3%) ARV-experienced patients at DRV start. The
median score was 8.3% (1st quartile 4.1%, 3rd quartile
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Figure 1 Kaplan-Meier curves of time to cardiovascular adverse event (CVAE). (A) All patients (N=875). (B) Patients without previous CVD (N=789).
Antinori et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Drug Design, Development and Therapy 2019:131674
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
9.
14
9.
73
.1
13
 o
n 
17
-J
un
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
T
ab
le
4
Si
ze
an
d
C
VA
E
co
un
ts
in
pa
tie
nt
su
bs
et
s
de
ﬁ
ne
d
by
PS
fo
r
D
RV
do
se
s
P
S
fo
r
60
0
m
g
b
.i.
d
.
D
R
V
C
o
h
o
rt
S
u
b
se
t
sp
ec
iﬁ
ca
ti
o
n
N
o
f
p
ts
N
o
f
an
y
C
V
A
E
/
N
o
f
p
ts
D
R
V
d
o
se
(m
g)
at
st
u
d
y
st
ar
t
D
R
V
d
o
se
(m
g)
m
ax
im
u
m
u
p
to
st
u
d
y
st
ar
t
80
0
q
.d
.
60
0
b
.i.
d
.
80
0
q
.d
.
60
0
b
.i.
d
.
0.
10
to
0.
15
To
ta
l
19
2
0
/
17
0
0
/
22
0
/
17
0
0
/
22
D
RV
-n
aï
ve
A
RV
-n
aï
ve
A
ll
11
7
0
/
10
5
0
/
12
D
RV
-e
xp
.d
no
n
EA
P
a)
A
RV
-n
aï
ve
at
D
RV
st
ar
t
75
0
/
65
0
/
10
0
/
65
0
/
10
0.
50
to
0.
65
To
ta
l
21
8
2
/
88
5
/
13
0
2
/
87
5
/
13
1
D
RV
-e
xp
.d
no
n
EA
P
A
ll
ex
cl
ud
in
g
(a
)
(b
)
(c
)
an
d
(d
)
15
7
2
/
59
3
/
98
2
/
58
3
/
99
D
RV
-n
aï
ve
A
RV
-e
xp
.d
A
ll
ex
cl
ud
in
g
(e
)
an
d
(f)
61
0
/
29
2
/
32
0.
85
to
0.
95
To
ta
l
19
8
2
/
27
5
/
17
2
2
/
20
5
/
17
9
D
RV
-e
xp
.d
no
n
EA
P
b)
A
RV
-e
xp
.d
at
D
RV
st
ar
t
an
d
D
RV
at
st
ud
y
st
ar
t
fo
r
2-
3
yr
s
94
0
/
14
3
/
80
0
/
7
3
/
87
D
RV
-e
xp
.d
no
n
EA
P
c)
A
RV
th
er
ap
y
fo
r
>
9
yr
s
at
D
RV
st
ar
t
an
d
D
RV
at
st
ud
y
st
ar
t
fo
r
1-
2
yr
s
50
2
/
7
1
/
43
2
/
7
1
/
43
D
RV
-n
aï
ve
A
RV
-e
xp
.d
e)
(H
IV
-R
N
A
≥
10
00
00
/m
L
or
C
D
4+
<
10
0
/µ
L)
at
st
ud
y
st
ar
t
21
0
/
2
0
/
19
D
RV
-n
aï
ve
A
RV
-e
xp
.d
f)
(H
IV
-R
N
A
≥
50
-9
99
99
/m
L
or
C
D
4+
10
0-
19
9
/µ
L)
at
st
ud
y
st
ar
t
an
d
A
RV
th
er
ap
y
fo
r
>
6.
5
yr
s
at
st
ud
y
st
ar
t,
ex
cl
ud
in
g
(e
).
34
0
/
4
1
/
30
≈
1
(*
)
To
ta
l
26
6
0
/
3
9
/
26
3
0
/
0
9
/
26
6
D
RV
-e
xp
.d
ex
EA
P
A
ll
23
5
0
/
3
9
/
23
2
0
/
0
9
/
23
5
D
RV
-e
xp
.d
no
n
EA
P
d)
D
RV
at
st
ud
y
st
ar
t
fo
r
≥
3
yr
s
31
0
/
0
0
/
31
0
/
0
0
/
31
N
o
te
:
*)
1
at
D
RV
st
ar
t,
0.
99
at
st
ud
y
st
ar
t
as
3
pa
tie
nt
s
ha
d
re
du
ce
d
th
e
do
se
.
A
b
b
re
vi
at
io
n
s:
PS
,p
ro
pe
ns
ity
sc
or
e;
C
VA
E,
ca
rd
io
va
sc
ul
ar
ad
ve
rs
e
ev
en
t;
A
RV
,a
nt
ir
et
ro
vi
ra
l;
D
RV
,d
ar
un
av
ir
;q
.d
.,
on
ce
a
da
y;
b.
i.d
.,
tw
ic
e
da
ily
.
Dovepress Antinori et al
Drug Design, Development and Therapy 2019:13 submit your manuscript | www.dovepress.com
DovePress
1675
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
9.
14
9.
73
.1
13
 o
n 
17
-J
un
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
T
ab
le
5
In
ci
de
nc
e
ra
te
s
of
C
VA
Es
em
er
gi
ng
du
ri
ng
th
e
st
ud
y
ac
co
rd
in
g
to
D
RV
do
se
at
st
ud
y
st
ar
t
C
V
D
h
is
to
ry
C
V
A
E
ty
p
e
D
R
V
d
o
se
at
st
u
d
y
st
ar
t
(m
g)
P
ro
p
en
si
ty
sc
o
re
s
fo
r
D
R
V
d
o
se
60
0
m
g
b
.i.
d
.
O
ve
ra
ll
0.
10
-
0.
15
0.
50
-
0.
65
0.
85
-
0.
95
≈
1
u
n
st
ra
ti
ﬁ
ed
N
/
yr
s
IR
(9
5%
C
I)
N
/
yr
s
IR
(9
5%
C
I)
N
/
yr
s
IR
(9
5%
C
I)
N
/
yr
s
IR
(9
5%
C
I)
N
/
yr
s
IR
(9
5%
C
I)
A
ny
A
ny
80
0
q.
d.
0
/
27
5
0
(0
,1
3)
2
/
11
4
18
(2
,6
3)
2
/
43
46
(N
E)
0
/
7
0
(N
E)
4
/
43
9
9
(2
,2
3)
60
0
b.
i.d
.
0
/
33
0
(N
E)
5
/
21
3
23
(8
,5
5)
5
/
31
6
16
(5
,3
7)
9
/
56
5
16
(7
,3
0)
19
/
11
27
17
(1
0,
26
)
G
en
er
al
(F
ra
m
in
gh
am
)
80
0
q.
d.
0
/
27
5
0
(0
,1
3)
2
/
11
4
18
(2
,6
3)
2
/
43
46
(N
E)
0
/
7
0
(N
E)
4
/
43
9
9
(2
,2
3)
60
0
b.
i.d
.
0
/
33
0
(N
E)
3
/
21
3
14
(3
,4
1)
4
/
31
6
13
(3
,3
2)
8
/
56
5
14
(6
,2
8)
15
/
11
27
13
(7
,2
2)
H
ar
d
+
su
rg
er
y
(D
A
D
)
80
0
q.
d.
0
/
27
5
0
(0
,1
3)
1
/
11
4
9
(0
,4
9)
2
/
43
46
(N
E)
0
/
7
0
(N
E)
3
/
43
9
7
(1
,2
0)
60
0
b.
i.d
.
0
/
33
0
(N
E)
1
/
21
3
5
(0
,2
6)
4
/
31
6
13
(3
,3
2)
6
/
56
5
11
(4
,2
3)
11
/
11
27
10
(5
,1
7)
H
ar
d
(A
C
C
/A
H
A
)
80
0
q.
d.
0
/
27
5
0
(0
,1
3)
1
/
11
4
9
(0
,4
9)
2
/
43
46
(N
E)
0
/
7
0
(N
E)
3
/
43
9
7
(1
,2
0)
60
0
b.
i.d
.
0
/
33
0
(N
E)
1
/
21
3
5
(0
,2
6)
3
/
31
6
9
(2
,2
8)
6
/
56
5
11
(4
,2
3)
10
/
11
27
9
(4
,1
6)
N
o
A
ny
80
0
q.
d.
0
/
26
7
0
(0
,1
4)
2
/
10
7
19
(2
,6
7)
1
/
38
27
(N
E)
0
/
7
0
(N
E)
3
/
41
9
7
(1
,2
1)
60
0
b.
i.d
.
0
/
31
0
(N
E)
5
/
18
8
27
(9
,6
2)
3
/
28
9
10
(2
,3
0)
6
/
48
6
12
(5
,2
7)
14
/
99
3
14
(8
,2
4)
G
en
er
al
(F
ra
m
in
gh
am
)
80
0
q.
d.
0
/
26
7
0
(0
,1
4)
2
/
10
7
19
(2
,6
7)
1
/
38
27
(N
E)
0
/
7
0
(N
E)
3
/
41
9
7
(1
,2
1)
60
0
b.
i.d
.
0
/
31
0
(N
E)
3
/
18
8
16
(3
,4
7)
2
/
28
9
7
(1
,2
5)
6
/
48
6
12
(5
,2
7)
11
/
99
3
11
(6
,2
0)
H
ar
d
(A
C
C
/A
H
A
)
(*
)
80
0
q.
d.
0
/
26
7
0
(0
,1
4)
1
/
10
7
9
(0
,5
2)
1
/
38
27
(N
E)
0
/
7
0
(N
E)
2
/
41
9
5
(1
,1
7)
60
0
b.
i.d
.
0
/
31
0
(N
E)
1
/
18
8
5
(0
,3
0)
2
/
28
9
7
(1
,2
5)
4
/
48
6
8
(2
,2
1)
7
/
99
3
7
(3
,1
5)
N
o
te
:
*s
am
e
as
ha
rd
+
su
rg
er
y
(D
A
D
).
A
b
b
re
vi
at
io
n
s:
C
VA
E,
ca
rd
io
va
sc
ul
ar
ad
ve
rs
e
ev
en
t;
C
V
D
,
ca
rd
io
va
sc
ul
ar
di
se
as
e;
A
C
C
/A
H
A
,
A
m
er
ic
an
C
ol
le
ge
of
C
ar
di
ol
og
y/
A
m
er
ic
an
H
ea
rt
A
ss
oc
ia
tio
n;
N
,
nu
m
be
r
of
ev
en
ts
;
IR
,
in
ci
de
nc
e
ra
te
as
N
/1
00
0
pa
tie
nt
-y
ea
rs
;
C
I,
co
nﬁ
de
nc
e
in
te
rv
al
;N
E,
no
t
es
tim
at
ed
(le
ss
th
an
10
0
pa
tie
nt
-y
ea
rs
);
q.
d.
,o
nc
e
a
da
y;
b.
i.d
.,
tw
ic
e
da
ily
.
Antinori et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Drug Design, Development and Therapy 2019:131676
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
9.
14
9.
73
.1
13
 o
n 
17
-J
un
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
T
ab
le
6
M
ai
n
re
su
lts
of
C
ox
m
od
el
s
fo
r
pr
im
ar
y
Fr
am
in
gh
am
-t
yp
e
ge
ne
ra
lC
VA
Es
(1
4
ev
en
ts
)
an
d
fo
r
an
y
C
VA
Es
(2
3
ev
en
ts
)
B
as
el
in
e
va
ri
ab
le
s
L
ev
el
o
r
sc
al
ea
C
V
A
E
ty
p
e
C
ov
ia
ri
at
es
A
ll
p
at
ie
n
ts
A
R
V
-e
xp
er
ie
n
ce
d
at
D
R
V
st
ar
t
N
H
R
(9
5%
C
I)
p
N
H
R
(9
5%
C
I)
p
FR
S
+
10
0%
Fr
am
in
gh
am
-t
yp
e,
pr
im
ar
y
/
62
6
3.
05
(1
.7
1,
5.
44
)
0.
00
02
48
5
2.
92
(1
.6
3,
5.
22
)
0.
00
03
A
ge
+
25
%
Fr
am
in
gh
am
-t
yp
e,
pr
im
ar
y
/
78
9
3.
20
(1
.5
4,
6.
65
)
0.
00
19
60
4
3.
39
(1
.5
4,
7.
43
)
0.
00
23
A
ny
,p
ri
m
ar
y
or
se
co
nd
ar
y
/
87
5
3.
67
(2
.1
1,
6.
37
)
<
0.
00
01
68
3
3.
73
(2
.1
1,
6.
59
)
<
0.
00
01
A
ny
,p
ri
m
ar
y
or
se
co
nd
ar
y
SB
P
71
0
2.
78
(1
.5
8,
4.
89
)
0.
00
04
55
7
2.
83
(1
.5
9,
5.
04
)
0.
00
04
SB
P
+
10
%
Fr
am
in
gh
am
-t
yp
e,
pr
im
ar
y
/
64
4
2.
04
(1
.3
8,
3.
02
)
0.
00
04
49
7
1.
94
(1
.3
1,
2.
87
)
0.
00
09
A
ny
,p
ri
m
ar
y
or
se
co
nd
ar
y
A
ge
71
0
1.
76
(1
.2
6,
2.
44
)
0.
00
08
55
7
1.
71
(1
.2
3,
2.
38
)
0.
00
13
Pr
ev
io
us
C
V
D
ye
s
(v
s
no
)
A
ny
,p
ri
m
ar
y
or
se
co
nd
ar
y
A
ge
,S
BP
71
0
1.
09
(0
.3
7,
3.
23
)
0.
87
55
7
1.
01
(0
.3
4,
3.
03
)
0.
99
G
en
de
r
F
(v
s
M
)
Fr
am
in
gh
am
-t
yp
e,
pr
im
ar
y
A
ge
78
9
1.
09
(0
.3
0,
3.
99
)
0.
89
60
4
1.
02
(0
.2
8,
3.
73
)
0.
98
A
ny
,p
ri
m
ar
y
or
se
co
nd
ar
y
A
ge
,S
BP
71
0
1.
51
(0
.4
8,
4.
73
)
0.
48
55
7
1.
39
(0
.4
4,
4.
35
)
0.
58
BM
I
+
10
%
Fr
am
in
gh
am
-t
yp
e,
pr
im
ar
y
A
ge
66
0
1.
31
(0
.9
4,
1.
82
)
0.
11
50
1
1.
26
(0
.9
1,
1.
75
)
0.
16
A
ny
,p
ri
m
ar
y
or
se
co
nd
ar
y
A
ge
,S
BP
66
5
0.
97
(0
.7
2,
1.
31
)
0.
83
52
4
0.
95
(0
.7
1,
1.
28
)
0.
74
D
ia
be
te
s
ye
s
(v
s
no
)
Fr
am
in
gh
am
-t
yp
e,
pr
im
ar
y
A
ge
78
9
1.
80
(0
.3
8,
8.
51
)
0.
46
60
4
1.
84
(0
.3
9,
8.
73
)
0.
44
A
ny
,p
ri
m
ar
y
or
se
co
nd
ar
y
A
ge
,S
BP
71
0
0.
65
(0
.1
4,
2.
88
)
0.
57
55
7
0.
75
(0
.1
7,
3.
33
)
0.
70
Sm
ok
in
g
ye
s
(v
s
no
)
Fr
am
in
gh
am
-t
yp
e,
pr
im
ar
y
A
ge
77
5
2.
36
(0
.7
7,
7.
27
)
0.
13
59
5
2.
09
(0
.7
0,
6.
52
)
0.
20
A
ny
,p
ri
m
ar
y
or
se
co
nd
ar
y
A
ge
,S
BP
70
3
1.
96
(0
.8
0,
4.
82
)
0.
14
55
1
1.
78
(0
.7
3,
4.
34
)
0.
20
Se
ru
m
to
ta
lc
ho
le
st
er
ol
+
25
%
Fr
am
in
gh
am
-t
yp
e,
pr
im
ar
y
A
ge
67
3
1.
45
(0
.8
7,
2.
43
)
0.
15
52
2
1.
29
(0
.7
4,
2.
25
)
0.
36
A
ny
,p
ri
m
ar
y
or
se
co
nd
ar
y
A
ge
,S
BP
60
0
1.
39
(0
.8
7,
2.
20
)
0.
17
48
0
1.
23
(0
.7
6,
2.
01
)
0.
40
Se
ru
m
LD
L
ch
ol
es
te
ro
l
+
25
%
Fr
am
in
gh
am
-t
yp
e,
pr
im
ar
y
A
ge
58
8
1.
35
(0
.9
0,
2.
03
)
0.
14
46
5
1.
26
(0
.8
2,
1.
92
)
0.
29
A
ny
,p
ri
m
ar
y
or
se
co
nd
ar
y
A
ge
,S
BP
52
2
1.
31
(0
.9
1,
1.
87
)
0.
14
42
8
1.
22
(0
.8
4,
1.
76
)
0.
30
Se
ru
m
H
D
L
ch
ol
es
te
ro
l
+
25
%
Fr
am
in
gh
am
-t
yp
e,
pr
im
ar
y
A
ge
59
5
0.
96
(0
.6
5,
1.
42
)
0.
83
47
0
0.
85
(0
.5
7,
1.
29
)
0.
46
A
ny
,p
ri
m
ar
y
or
se
co
nd
ar
y
A
ge
,S
BP
53
0
1.
10
(0
.7
9,
1.
53
)
0.
57
43
4
0.
99
(0
.6
9,
1.
41
)
0.
95
C
D
C
st
ag
e
C
(v
s
A
-B
)
Fr
am
in
gh
am
-t
yp
e,
pr
im
ar
y
A
ge
78
9
1.
14
(0
.3
9,
3.
32
)
0.
80
60
4
1.
11
(0
.3
9,
3.
21
)
0.
84
A
ny
,p
ri
m
ar
y
or
se
co
nd
ar
y
A
ge
,S
BP
71
0
0.
93
(0
.3
9,
2.
19
)
0.
86
55
7
0.
90
(0
.3
8,
2.
12
)
0.
81
H
IV
-R
N
A
≥
50
/m
L
(v
s
<
50
)
Fr
am
in
gh
am
-t
yp
e,
pr
im
ar
y
A
ge
58
8
1.
15
(0
.3
2,
4.
13
)
0.
83
A
ny
,p
ri
m
ar
y
or
se
co
nd
ar
y
A
ge
,S
BP
54
4
0.
73
(0
.2
1,
2.
51
)
0.
61
C
D
4+
+
50
%
Fr
am
in
gh
am
-t
yp
e,
pr
im
ar
y
A
ge
58
9
0.
96
(0
.7
2,
1.
28
)
0.
78
A
ny
,p
ri
m
ar
y
or
se
co
nd
ar
y
A
ge
,S
BP
54
4
1.
09
(0
.8
0,
1.
49
)
0.
57
N
o
te
:
a
H
R
s
fo
r
co
nt
in
uo
us
va
ri
ab
le
s
re
fe
r
to
re
la
tiv
e
in
cr
ea
se
s
of
th
e
va
ri
ab
le
va
lu
e
by
th
e
am
ou
nt
sp
ec
iﬁ
ed
;H
R
s
fo
r
cl
as
s
va
ri
ab
le
s
re
fe
r
to
th
e
le
ve
ls
pe
ci
ﬁ
ed
ve
rs
us
th
e
al
te
rn
at
iv
e
le
ve
l.
A
b
b
re
vi
at
io
n
s:
H
R
,h
az
ar
d
ra
tio
;C
I,
co
nﬁ
de
nc
e
in
te
rv
al
;A
RV
,a
nt
ir
et
ro
vi
ra
l;
D
RV
,d
ar
un
av
ir
;C
V
D
,c
ar
di
ov
as
cu
la
r
di
se
as
e;
C
VA
E,
ca
rd
io
va
sc
ul
ar
ad
ve
rs
e
ev
en
t;
FR
S,
Fr
am
in
gh
am
ri
sk
sc
or
e;
BM
I,
bo
dy
m
as
s
in
de
x;
SB
P,
sy
st
ol
ic
bl
oo
d
pr
es
su
re
;H
D
L,
hi
gh
de
ns
ity
lip
op
ro
te
in
;L
D
L,
lo
w
de
ns
ity
lip
op
ro
te
in
;H
IV
-R
N
A
,h
um
an
im
m
un
od
eﬁ
ci
en
cy
vi
ru
s
ri
bo
nu
cl
ei
c
ac
id
;C
D
4+
,c
la
ss
of
di
ffe
re
nt
ia
tio
n
4
(T
-h
el
pe
r)
;C
D
C
,C
en
te
r
fo
r
D
is
ea
se
C
on
tr
ol
an
d
Pr
ev
en
tio
n.
Dovepress Antinori et al
Drug Design, Development and Therapy 2019:13 submit your manuscript | www.dovepress.com
DovePress
1677
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
9.
14
9.
73
.1
13
 o
n 
17
-J
un
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
T
ab
le
7
C
ox
m
od
el
s
fo
r
an
y
pr
im
ar
y
or
se
co
nd
ar
y
C
VA
Es
(2
3
ev
en
ts
)
in
al
lp
at
ie
nt
s
(N
=
87
5)
V
ar
ia
b
le
s
at
o
r
u
p
to
b
as
el
in
e
L
ev
el
o
r
sc
al
ea
S
iz
e
N
U
n
iv
ar
ia
te
an
al
ys
is
b
M
o
d
el
s
b
as
ed
o
n
ag
e
an
d
S
B
P
c
b
M
o
d
el
s
b
as
ed
o
n
ag
e,
S
B
P
c
,H
IV
+
ti
m
e
b
ef
o
re
A
R
V
sd
,
an
d
A
R
V
ti
m
ee
p
re
-D
R
V
f
b
M
o
d
el
s
b
as
ed
o
n
ag
e,
S
B
P
c
,
H
IV
+
ti
m
e
b
ef
o
re
A
R
V
sd
,a
n
d
to
ta
l
A
R
V
ti
m
ee
H
R
(9
5%
C
I)
p
H
R
(9
5%
C
I)
p
H
R
(9
5%
C
I)
p
H
R
(9
5%
C
I)
p
A
ge
+
25
%
87
5
3.
67
(2
.1
1,
6.
37
)
<
0.
00
01
2.
87
(1
.6
5,
4.
98
)
0.
00
02
3.
20
(1
.7
8,
5.
74
)
<
0.
00
01
3.
25
(1
.8
0,
5.
87
)
<
0.
00
01
SB
P
+
10
%
71
0
2.
08
(1
.5
2,
2.
85
)
<
0.
00
01
SB
Pc
+
10
%
87
5
2.
09
(1
.5
6,
2.
79
)
<
0.
00
01
1.
79
(1
.3
0,
2.
45
)
0.
00
03
1.
75
(1
.2
7,
2.
40
)
0.
00
06
1.
76
(1
.2
8,
2.
42
)
0.
00
05
T
im
e
si
nc
e
H
IV
+
to
ta
l
+
10
0%
(g
)
85
8
1.
43
(0
.9
8,
2.
10
)
0.
06
2
1.
41
(0
.9
4,
2.
11
)
0.
09
8
T
im
e
si
nc
e
H
IV
+
d
to
ta
l
+
10
0%
(g
)
87
5
1.
37
(0
.9
8,
1.
91
)
0.
06
2
1.
35
(0
.9
5,
1.
93
)
0.
09
7
H
IV
+
tim
e
be
fo
re
A
RV
s
+
10
0%
(g
)
82
6
1.
13
(0
.9
9,
1.
30
)
0.
06
9
1.
14
(0
.9
9,
1.
32
)
0.
06
4
H
IV
+
tim
ed
be
fo
re
A
RV
se
+
10
0%
(g
)
87
5
1.
12
(0
.9
8,
1.
28
)
0.
08
6
1.
13
(0
.9
9,
1.
30
)
0.
07
1
1.
11
(0
.9
6,
1.
27
)
0.
16
1.
11
(0
.9
6,
1.
28
)
0.
16
A
RV
th
er
ap
y
du
ra
tio
n
to
ta
l
+
10
0%
(g
)
83
5
1.
23
(0
.9
9,
1.
54
)
0.
06
5
1.
20
(0
.9
5,
1.
52
)
0.
13
A
RV
th
er
ap
y
du
ra
tio
ne
to
ta
l
+
10
0%
(g
)
87
5
1.
22
(0
.9
8,
1.
53
)
0.
07
2
1.
19
(0
.9
5,
1.
51
)
0.
13
1.
16
(0
.9
2,
1.
47
)
0.
21
A
RV
th
er
ap
y
du
ra
tio
n
pr
e-
D
RV
+
10
0%
(g
)
83
0
1.
17
(1
.0
0,
1.
37
)
0.
05
4
1.
14
(0
.9
6,
1.
35
)
0.
13
A
RV
th
er
ap
y
du
ra
tio
ne
pr
e-
D
RV
f
+
10
0%
(g
)
87
5
1.
16
(0
.9
9,
1.
36
)
0.
06
1
1.
13
(0
.9
6,
1.
34
)
0.
14
1.
11
(0
.9
3,
1.
31
)
0.
25
D
RV
th
er
ap
y
du
ra
tio
n
+
10
0%
(g
)
87
0
1.
09
(0
.9
6,
1.
22
)
0.
17
1.
06
(0
.9
4,
1.
20
)
0.
30
1.
02
(0
.9
0,
1.
16
)
0.
75
D
RV
th
er
ap
y
du
ra
tio
nf
+
10
0%
(g
)
87
5
1.
08
(0
.9
6,
1.
22
)
0.
18
1.
06
(0
.9
4,
1.
20
)
0.
31
1.
02
(0
.9
0,
1.
16
)
0.
77
C
um
ul
at
ed
D
RV
do
se
+
10
0%
(g
)
87
0
1.
08
(0
.9
6,
1.
21
)
0.
18
1.
06
(0
.9
4,
1.
19
)
0.
32
1.
02
(0
.9
0,
1.
15
)
0.
79
C
um
ul
at
ed
D
RV
do
se
f
+
10
0%
(g
)
87
5
1.
08
(0
.9
6,
1.
21
)
0.
19
1.
06
(0
.9
4,
1.
19
)
0.
33
1.
02
(0
.9
0,
1.
15
)
0.
81
M
ax
im
um
D
RV
da
ily
do
se
12
00
m
g
(v
s
80
0)
87
5
1.
78
(0
.6
1,
5.
30
)
0.
29
1.
45
(0
.4
9,
4.
33
)
0.
50
0.
83
(0
.2
5,
2.
76
)
0.
76
0.
78
(0
.2
4,
2.
57
)
0.
69
C
ur
re
nt
D
RV
da
ily
do
se
12
00
m
g
(v
s
80
0)
87
5
1.
92
(0
.6
5,
5.
67
)
0.
24
1.
53
(0
.5
1,
4.
55
)
0.
45
0.
91
(0
.2
8,
2.
98
)
0.
87
0.
86
(0
.2
6,
2.
78
)
0.
80
N
o
te
s:
a
H
R
s
fo
r
co
nt
in
uo
us
va
ri
ab
le
s
re
fe
r
to
re
la
tiv
e
in
cr
ea
se
s
of
th
e
va
ri
ab
le
va
lu
e
by
th
e
am
ou
nt
sp
ec
iﬁ
ed
;H
R
s
fo
r
cl
as
s
va
ri
ab
le
s
re
fe
r
to
th
e
le
ve
ls
pe
ci
ﬁ
ed
ve
rs
us
th
e
al
te
rn
at
iv
e
le
ve
l.
b
O
th
er
va
ri
ab
le
s
ar
e
ad
de
d
in
tu
rn
to
th
e
ba
si
c
m
od
el
.
c
In
cl
ud
in
g
16
5
im
pu
te
d
va
lu
es
.
d
In
cl
ud
in
g
17
im
pu
te
d
va
lu
es
.
e
In
cl
ud
in
g
40
im
pu
te
d
va
lu
es
.
f I
nc
lu
di
ng
5
va
lu
es
ob
ta
in
ed
by
im
pu
tin
g
th
e
da
te
of
D
RV
st
ar
t.
g
D
ou
bl
in
g
or
10
0%
in
cr
ea
se
af
te
r
ad
di
ng
1
un
it
to
al
lo
w
lo
g-
tr
an
sf
or
m
at
io
n
of
va
ri
ab
le
s
th
at
in
cl
ud
e
0
va
lu
es
:l
og
2
(d
ay
s+
1)
fo
r
tim
e
va
ri
ab
le
s
an
d
lo
g 2
(g
ra
m
s+
1)
fo
r
cu
m
ul
at
ed
do
se
.
A
b
b
re
vi
at
io
n
s:
H
R
,h
az
ar
d
ra
tio
;C
I,
co
nﬁ
de
nc
e
in
te
rv
al
;H
IV
+
,p
os
iti
ve
to
hu
m
an
im
m
un
od
eﬁ
ci
en
cy
vi
ru
s;
A
RV
,a
nt
ir
et
ro
vi
ra
l;
D
RV
,d
ar
un
av
ir
;C
VA
E,
ca
rd
io
va
sc
ul
ar
ad
ve
rs
e
ev
en
t.
Antinori et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Drug Design, Development and Therapy 2019:131678
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
9.
14
9.
73
.1
13
 o
n 
17
-J
un
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
14.1%) overall, as reported in Table 1; the median
score was 26.1% (15.2, 45.4) in 13 patients who actu-
ally experienced Framingham-type CVAEs during the
study, and 8.1% (4.1, 13.8) in patients without such
events. Notably, the median score was 9.2% (4.5, 14.9)
in patients given ARV therapies before DRV start and
6.2% (3.2, 10.3) in ARV-naïve patients at DRV start.
In these 626 patients with 13 primary Framingham-
type CVAEs actually observed, 10 such events were
expected during the study, given their Framingham score,
by the accelerated risk model described in the Methods
section, while 13 were expected assuming that the risk was
uniformly distributed over 10 years. Considering all 789
patients without previous CVDs (including 163 with
incomplete data), with an actual observation of 14
Framingham-type CVAEs, the number of expected events
of this type was 12 in the accelerated-risk model and 16 in
the constant-risk hypothesis, when imputing the most
likely values for missing data; instead, when imputing
the optimal values, the expected events were 11 and 15,
respectively. As a reference, four (assuming an accelerated
IR), or six (assuming a constant IR) Framingham-type
CVAEs would be expected in an age- and gender-
matched population with all optimal values of modiﬁable
risk factors.
The ACC/AHA hard ASCVD 10-year risk could be
calculated in 451 (57.2%) of all 789 patients without
previous CVDs. The median score was 4.0% (1st quartile
1.8%, 3rd quartile 7.8%) overall, 8.2% (3.8, 24.8) in seven
patients who experienced these events during the study
and 4.0% (1.8, 7.8) in those who did not.
Cardiovascular events by risk factors at
baseline
The main results of the Cox models examining the asso-
ciation between the incidence of CVAEs and patient char-
acteristics are reported in Table 6. Details of all analysis
models are provided in the Supplementary materials
(Tables S4–S7). The values of the variables more likely
associated with CVD risk in the individual patients who
had CVAEs are listed in the Supplementary materials
(Listing III).
The Framingham primary CVD 10-year risk index was
strongly (p<0.001) associated with Framingham-type gen-
eral CVAEs, both in the analysis of all patients and in the
analysis of patients who were ARV-experienced at DRV
start (thereby excluding the 192 patients ARV-naïve at
DRV start, who had no CVAE). The predictive model
based on the Framingham risk score was more efﬁcient
(according to Akaike’s information criterion) than the
models containing any combination of other variables,
either included in the score calculation or not; other vari-
ables not included in the Framingham risk score had no
signiﬁcant effect after adjusting for it. The Framingham
risk index, however, was not available in approximately
20% of the patients, and it was not used in the models for
any primary or secondary CVAEs, as it was developed for
primary events only. Age was the single variable without
missing data that was most signiﬁcantly (p<0.001) asso-
ciated with both Framingham-type general CVAEs and all
CVAEs in univariate analyses. Multivariable analyses
showed that age and SBP at enrolment were the most
important (p<0.01) independent predictors of both
Framingham-type CVAEs and of any CVAEs, consistently
across various models (Table 6 and Supplementary mate-
rials, Tables S4–S7) including the models examining the
possible effect of previous exposures (Table 7). The
adjusted HR for age was approximately 2.8 for a 25%
increase, eg, from 30 to 37.5, 40 to 50, or 50 to
62.5 years. The adjusted HR for SBP was 1.7–1.8 for
a 10% increase, eg, from 120 to 132, 132 to 145, or 145
to 160 mmHg. Patients who had any CVAE during the
study were 56±9 years old and their SBP was 136
±18 mmHg at study entry (mean ± SD), compared with
46±9 years and 122±13 mmHg in patients without CVAEs.
Other traditional risk factors, including gender, dia-
betes, BMI, serum lipids, and eGFR, were at most weakly
and not signiﬁcantly (p>0.10) associated with CVAEs
when controlling for age (in primary Framingham-type
CVAE models) or for age and SBP (in all-type CVAE
models) (Table 6 and Supplementary materials, Tables
S4–S7). Adjusted HRs for a 25% increase of total choles-
terol (eg, from 200 to 250 or from 250 to 312.5 mg/dL) or
LDL cholesterol (eg, from 130 to 162.5 or from 162.4 to
203 mg/dL) ranged from 1.07 to 1.45 across models, with
p-values of 0.14 or greater. Smoking (Table 6) and family
history of CVD (Supplementary materials) did not achieve
statistical signiﬁcance although they were associated with
a twofold increase in risk. Patients with previous CVDs
had a CVAE risk 2.8 times higher than patients without
previous CVDs in the univariate analysis, but this differ-
ence was no longer observed after adjustment for age and
SBP (Table 6 and Supplementary materials). The associa-
tion with baseline use of anticoagulant agents, antihyper-
tensives and statins in univariate analysis but not in the
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multivariable analysis is also explained by the confound-
ing effect of older age and higher SBP in patients taking
these drugs (Supplementary materials). HIV-speciﬁc fac-
tors such as viral load, CD4+ count and CDC stage were
not associated with CVAE incidence (Table 6).
Cardiovascular events by HIV infection
duration and previous exposure to
therapy
The effect of HIV infection length and exposure to ARV
therapy, including DRV, on the risk of any CVAE was
further examined in all patients by the Cox models
reported in Table 7. Time since HIV+ diagnosis is
reported both as the total time up to study entry and as
the time from diagnosis to ARV therapy start, and ARV
therapy duration is reported both as total time up to
study entry and as the partial time up to DRV start.
When both durations were included in the same model,
overlaps between the exposure times were avoided. The
variables used for adjustment included imputed values to
avoid patient exclusion due to missing data; the HRs for
these variables with and without imputation were always
close enough to justify this step. In the univariate ana-
lysis, all variables that represent the length of HIV
infection and exposure to ARV therapy were associated
with CVAE incidence with p-values of 0.05–0.09, while
the variables that represent exposure to DRV showed
a weaker association with non-signiﬁcant p-values.
Adjusting for age and SBP, the risk factors highlighted
the most relevant in the previous analyses, somewhat
attenuated all these associations. When additionally
adjusting for time from HIV+ diagnosis to ARV therapy
start and for ARV therapy duration before DRV start, the
association of previous DRV therapy duration and cumu-
lated DRV dose with CVAE incidence was further
reduced, with HRs around 1. This model (or a similar
one with ARV therapy duration up to study entry rather
than up to DRV start) overrides the unadjusted differ-
ences between DRV daily doses, yielding adjusted HRs
of approximately 0.9 for 600 mg b.i.d. versus 800 mg
q.d. at study start. Such result is explained by the above
consideration that the PS for DRV 600 mg b.i.d. was
increased by longer histories of previous ARV therapy,
which are in turn associated with greater CVAE inci-
dence, and that patients with no previous ARV therapy,
who had no CVAE, were mostly given DRV 800 mg
q.d.
Cardiovascular events and biochemical
parameters during the study
The values of several biochemical parameters around the
CVAEs (within three months before or shortly after) were
compared with before-CVAE means (from baseline
included to CVAE excluded) in the same patients and
with average measures in patients without CVAEs.
Complete ﬁgures are provided in the Tables S8–S11.
The mean intrapatient change in lipid values registered
at the CVAE compared with the values before the CVAE
was +6 mg/dL for total cholesterol and +2 mg/dL for LDL
cholesterol. Compared to the average measures in patients
without CVAEs, values in patients who developed CVAEs
were 18 mg/dL higher at baseline for total cholesterol and
14 mg/dL higher for LDL cholesterol, while the means
throughout the study (before the CVAE) were higher by 11
and 10 mg/dL, respectively. These differences were not
statistically signiﬁcant (p>0.10), and were further attenu-
ated by excluding patients who were ARV-naive at DRV
start (with no CVAEs). Essentially no increase was found
for HDL cholesterol, triglycerides, and blood glucose. Of
19 CVAEs with available data, 2 were preceded by
hypercholesterolemia of DAIDS grade 3 (total cholesterol
≥300 mg/dL or LDL cholesterol ≥190 mg/dL).
CD4+ counts at baseline and throughout the study were
similar in patients with and without CVAEs. Two CVAEs,
of 20 with available data, were preceded by a CD4+ count
<200 cells/µL, including one with conﬁrmed HIV-RNA
>50 copies/mL.
Neutrophil counts around CVAEs were on average 20%
higher than the values previously measured in the same
patients and 32% higher than those measured in CVAE-free
patients. The neutrophil/lymphocyte ratio also increased at
the time of CVAEs (+28%within patients and +40%between
patients), as well as the total WBC count (+11% within
patients and +17% between patients). These results, how-
ever, were driven by the remarkably high neutrophil counts
that preceded three CVAEs (7.9, 10.3 and 10.6 103/µL),
while the other 15 CVAEs with available data were preceded
by normal neutrophil counts. Essentially no increase was
found for monocyte and platelet counts.
Discussion and conclusions
CV morbidity and mortality in HIV-infected subjects has
improved in the last few years.14,15 However, the risk of
incident CVDs is still greater in HIV-infected than in
uninfected subjects, even after adjustment for
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demographic characteristics and traditional risk
factors.16–19 The causes of this increased risk are only
partly understood; they may be related to HIV infection
itself or to therapy with ARV drugs, especially boosted
PIs, via increased serum levels of LDL cholesterol or
through metabolic changes such as lipodystrophy and
chronic inﬂammation.18,20,21 In this paper we provide
a description of all CVAEs that occurred during the
TMC114-HIV4042 study; the main efﬁcacy and overall
safety results were previously published.6
In this study we followed 875 HIV-infected subjects
for a total of 1,566 patient-years. The incidence of primary
CVAEs, expressed as number/1000 patient-year, was as
follows: any, 12; Framingham-type general, 10; DAD-
type and ACC/AHA-type hard, 6; and fatal, 2. All
CVAEs occurred in the 683 patients exposed to ARV
therapy before DRV start.
These results are better interpreted with respect to
underlying CVD risk. CVD risk scores, ie equations that
calculate the probability of CVDs in a given time frame
based on known risk factors, are available for the out-
comes reported above: Framingham,8 ACC/AHA7 and
DAD.22 However, only the Framingham risk could be
calculated in a sufﬁciently high proportion of our patients,
ie approximately 80%, as allowed by the existence of an
alternative Framingham function that uses BMI instead of
cholesterol values, which were frequently missing in our
study. Although the Framingham prediction functions
were developed in the general population, they have been
shown to correctly estimate the absolute CVD risk also in
HIV-infected patients.23,24 The ACC/AHA risk score
could be calculated in less than 60% of our sample, mainly
because of missing values of SBP and cholesterol. DAD
scores were not calculated because they require, in addi-
tion to the variables above, a three-level classiﬁcation of
smoking (current, ex, no) whereas a two-level classiﬁca-
tion (yes/no) was used in our study. Moreover, DAD
equations were developed for time-updated rather than
baseline values of quantitative variables, whereas post-
baseline blood pressure values were generally not avail-
able in our study.
CVD incidence is expected to increase during follow-
up as age, the main risk factor, also increases. Therefore,
to calculate the absolute risk over time periods shorter than
10 years, a correction derived from other Framingham
equations that account for an accelerated event time13
was used.11,12 On the other hand, empirical Kaplan-
Meier curves often show constant or nearly constant IRs
over 10 years.25,26 Using Framingham equations, the num-
ber of primary Framingham-type general CVDs expected
in our study was 12 assuming the accelerated event-time
model and 16 assuming constant IRs, compared to the 14
actually observed. This result should be viewed cautiously
due to the small number of events and the short follow-up
time compared to the 10 years for which the Framingham
functions were developed. However, it suggests that the
CVD risk in our patients, in spite of a long previous
exposure to HIV infection and ARV therapy for most of
them, was not increased compared to what expected in an
HIV-negative population matched for the traditional risk
factors.
We examined the role of possible risk factors in several
multivariable Cox models, both for primary Framingham-
type general CVAEs and for any primary or secondary
CVAEs. In predicting primary Framingham-type CVAEs,
the model based on the Framingham risk score was more
efﬁcient than the models containing any combination of
other covariates, including the variables used to calculate
the score. In patients who had all data required for calcu-
lating the scores, the median Framingham general CVD
risk at 10 years was 26.1% in patients who actually
experienced these events during the study and 8.1% in
patients who did not. Age and SBP at entry were by far
the most important independent predictors of
Framingham-type general CVAEs, aside from the
Framingham risk score to which both contribute, and of
any CVAEs. The association of age and SBP with the
incidence of CVAEs was highly signiﬁcant (p<0.01) across
all models. Patients who had any CVAE during the study
were on average 10 years older and had an SBP 14 mmHg
higher than patients without CVAEs. When controlling for
these two factors, no association with other factors, includ-
ing smoking, BMI, diabetes, serum lipids and eGFR, was
statistically signiﬁcant (p>0.05), but it should be noted that
the models had sufﬁcient power to highlight only very
strong associations as signiﬁcant. This was especially
true for binary variables, such as smoking and family
CVD history, which had p-values >0.10 across all models
in spite of HRs of almost 2. The risk of any CVAE in
patients with previous CVDs was approximately three
times that of patients without CVD; however, this unad-
justed difference was entirely explained by older age and
higher SBP values.
As previously reported,6,27 mean serum lipid concen-
trations during this study were stable in DRV-experienced
patients while in DRV-naïve patients, especially if
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ARV-naïve, they started from lower levels and increased
over 3–6 months to reach values similar to DRV-
experienced patients. The increase of non-HDL choles-
terol levels has been supposed to represent a connection
between ARV therapy and increased CVD risk, although
this may not necessarily be the only one.28,29 In our
study, mean LDL and total cholesterol in patients who
developed CVAEs were 14 and 18 mg/dL higher at base-
line, respectively, compared to patients who did not, and
10–11 times higher throughout the study; this may have
contributed to increased CVD risk. Multivariable models
showed that this contribution was smaller than that of age
and SBP and did not achieve statistical signiﬁcance.
Moreover, mean LDL and total cholesterol values were
fairly stable up to the time of CVAEs and around it. No
relevant change in blood glucose levels occurred during
the study6,27 nor was it associated with CVAEs in the
analysis reported here. HIV infection itself and the related
opportunistic infections have been suggested to contribute
to increase CVD risk through immunosuppression and
increased inﬂammation.18,20,21,30 Low CD4+ counts and
detectable viremia were independently associated with
increased CVD risk in several studies,31–35 (although
not all),36 as was the neutrophil/lymphocyte ratio26
among other markers of systemic inﬂammation. In this
study, we found no evidence of an association of
CD4+ counts or HIV-RNA load with CVAEs, while the
neutrophil/lymphocyte ratio was markedly increased
around the time of three CVAEs out of 18 with available
data. A recent systematic review of the literature showed
that other inﬂammatory markers (interleukin-6, high-
sensitivity C-reactive protein, lipoprotein-associated phos-
pholipase A2 and LDL subfraction Apo A-I) did not
increase during treatment with DRV/r and that lipid pro-
ﬁle changes were overall similar compared to ritonavir-
boosted atazanavir.37
Prolonged exposure to ARV drugs, especially PIs (or at
least some of them), has often been found to increase CVD
risk,28,29,38,39 although not all studies agree on this
point.31,40 The effects of previous exposure to HIV infection
and to ARV therapy on CVD risk can hardly be disen-
tangled because one is contained in the other. In our study,
both were moderately associated with the incidence of
CVAEs in the univariate analysis or in the multivariable
analysis adjusting for traditional factors. Previous exposure
to DRV, reported either as time or as cumulated dose,
showed a weaker association that was further reduced
after adjustment for age, SBP and the duration of HIV
infection until the start of ARV therapy and of ARV therapy
until DRV start. The possible relationship between daily
doses of DRV and CVD risk cannot be examined without
considering the confounding effect of the characteristics of
the patients for whom the alternative doses, 800 mg q.d. or
600 mg b.i.d., are indicated. The propensity to give DRV
600 mg b.i.d. was expectedly increased by longer histories
of previous ARV therapy, which were in turn associated
with greater CVAEs incidence; patients with no ARV ther-
apy before DRV, who had no CVAE, mostly received the
800 mg q.d. dose. Therefore, although the crude rate of
CVAEs in patients receiving DRV 600 mg b.i.d. was almost
twice that of patients receiving DRV 800 mg q.d.; this
apparent effect was mostly due to confounding by ARV
treatment history, and was no longer observed in stratiﬁed
analysis and in models that adjust for previous ARV history
in addition to traditional factors. These analyses, although
insufﬁciently powered, show the inadequacy of comparing
doses without accounting for the different characteristics of
the patients. A dosage of 600 mg b.i.d. may be considered
a proxy of more advanced disease, with more comorbidities
and exposure to more risk factors. Much larger studies that,
unlike the DAD, provide information on DRV dosing are
clearly required to clarify whether the dosing schedule is
related to CVD risk or simply reﬂect a bias due to the
preferred use of 600 mg b.i.d. in highly experienced popu-
lations. Even large studies, however, may fail to clarify this
issue if confounding by indication is complete or almost
complete or is not adequately adjusted for in the statistical
analysis.
In addition to the relatively small size of the population
studied, the analysis presented here has other limitations.
As it was not planned when the study was conducted,
relevant information such as blood pressure and serum
lipids was not as systematically collected as were virolo-
gical and immunological data. Indeed, blood pressure is
not routinely recorded in hospital charts except in patients
having known hypertension. Missing baseline data further
reduced the analysis sample size, and moreover, blood
pressure, a key predictor of CVAEs, was not measured
again during the study. Lack or incompleteness of relevant
information relating to traditional CV risk factors has been
a problem also in previous studies on the use of ARV
treatments in HIV-infected patients. Future prospective
studies should include the systematic collection of these
data, given the importance of CV risk assessment in this
population. The possible effect of individual ARV drugs
that have been reported to increase CV risk, such as
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abacavir and older PIs, could not be accounted for in the
multivariable analyses because of confounding with over-
all ARV therapy duration, and the limited sample size did
not allow the inclusion of both variables in the same
model. Furthemore, while the length of overall ARV expo-
sure was available, that of individual ARV drugs was not.
Another concerning issue is a possible selection bias.
Upon the inclusion in this study, 87% of the patients
were ARV-experienced, many of them for several years,
and 73% were DRV-experienced; to be enrolled, they had
obviously survived fatal events, including fatal CVDs,
were not lost to observation and had not discontinued
DRV for any reason. Whether this selection affected the
results of our analysis is uncertain.
In conclusion, we did not ﬁnd an increased CVD risk
in our patients, despite most of them had long previous
exposure to HIV infection and ARV therapy, compared to
what was expected in an HIV-negative population matched
for traditional risk factors. This is consistent with the
results of a recent review of data from pooled clinical
studies and pharmacovigilance reporting, which did not
ﬁnd any signal suggesting that CVD could be connected
with DRV use.4 Indeed, in our analysis two traditional
factors, age and blood pressure, were by far the most
signiﬁcant predictors of CVD risk in HIV patients treated
with DRV/r. Serum lipids, a traditional factor possibly
related to ARV therapy, and previous exposure to HIV
infection or ARV therapy were of lesser importance,
while CD4+ count and previous length of exposure to
DRV or DRV dose were not associated with CVD risk.
A lack of evidence of such associations is not proof that
they do not exist; they may have been not fully captured in
this study due to the small sample size or the other limita-
tions pointed at above. Our analysis, however, conﬁrms
that traditional factors were overwhelmingly important
compared to HIV-speciﬁc factors in the development of
CVDs.
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